{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:52:56Z","timestamp":1790553176994,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40257-015-0156-2","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T09:14:28Z","timestamp":1442913268000},"page":"457-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["New and Emerging Treatments for Rosacea"],"prefix":"10.1007","volume":"16","author":[{"given":"Lauren M.","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe Diana","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"156_CR1","unstructured":"Baldwin H. Psychosocial implications of rosacea. Dermatologist. 2012;Suppl.:2\u20134."},{"key":"156_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"156_CR3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1365-2133.2005.06895.x","volume":"153","author":"MA Gupta","year":"2005","unstructured":"Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey: Outpatient Department data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol. 2005;153(6):1176\u201381.","journal-title":"Br J Dermatol"},{"issue":"5","key":"156_CR4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaad.2014.05.036","volume":"71","author":"F Moustafa","year":"2014","unstructured":"Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014;71(5):973\u201380.","journal-title":"J Am Acad Dermatol."},{"issue":"6 Suppl 1","key":"156_CR5","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jaad.2013.04.041","volume":"69","author":"A Layton","year":"2013","unstructured":"Layton A, Thiboutot D. Emerging therapies in rosacea. J Am Acad Dermatol. 2013;69(6 Suppl 1):S57\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"3 Suppl","key":"156_CR6","first-page":"1","volume":"91","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91(3 Suppl):1\u20138.","journal-title":"Cutis"},{"key":"156_CR7","first-page":"694","volume":"11","author":"JQ Rosso Del","year":"2012","unstructured":"Del Rosso JQ, Gallo RL, Kircik L, et al. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. Drugs Dermatol. 2012;11:694\u2013700.","journal-title":"Drugs Dermatol"},{"key":"156_CR8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","volume":"15","author":"M Steinhoff","year":"2011","unstructured":"Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:2\u201311.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"5","key":"156_CR9","first-page":"234","volume":"92","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, et al. A status report from the American acne & rosacea society part one: disease state overview, general measures, topical therapy. Consensus recommendations on the management of rosacea. Cutis. 2013;92(5):234\u201340.","journal-title":"Cutis"},{"key":"156_CR10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2014.08.028","volume":"72","author":"AM Two","year":"2015","unstructured":"Two AM, Wu W, Gallo R, Hata T. Part I: introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72:749\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"156_CR11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/jid.2012.14","volume":"132","author":"KN Kanada","year":"2012","unstructured":"Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435\u201342.","journal-title":"J Invest Dermatol"},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12019-007-8003-x","volume":"33","author":"RD Wise","year":"2007","unstructured":"Wise RD. Submicrobial doxycycline and rosacea. Compr Ther. 2007;33:78\u201381.","journal-title":"Compr Ther"},{"key":"156_CR13","unstructured":"Merck & Co. Inc. Stromectal (ivermectin) tablets. 2010. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/stromectol\/stromectol_pi.pdf . Accessed 21 June 2015."},{"key":"156_CR14","first-page":"78","volume":"17","author":"I Khan","year":"2007","unstructured":"Khan I, Yasmin R. Ivermectin in the treatment of scabies. J Pakistan Assoc Dermatol. 2007;17:78\u201383.","journal-title":"J Pakistan Assoc Dermatol"},{"issue":"Suppl 1","key":"156_CR15","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0924-8579(01)00403-4","volume":"18","author":"K Yanagihara","year":"2001","unstructured":"Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis: pathophysiology and treatment mechanisms. Int J Antimicrob Agents. 2001;18(Suppl 1):S83\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"156_CR16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(24)35272-3","volume":"292","author":"A Ianaro","year":"2000","unstructured":"Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292(1):156\u201363.","journal-title":"J Pharmacol Exp Ther"},{"key":"156_CR17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1472-8206.2009.00684.x","volume":"23","author":"X Ci","year":"2009","unstructured":"Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol. 2009;23:449\u201355.","journal-title":"Fundam Clin Pharmacol"},{"key":"156_CR18","first-page":"316","volume":"13","author":"L Stein","year":"2014","unstructured":"Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1\u00a0% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13:316\u201323.","journal-title":"J Drugs Dermatol"},{"key":"156_CR19","unstructured":"Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J. Long-term safety of ivermectin 1\u00a0% cream vs azelaic acid 15\u00a0% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13:1380\u20136."},{"issue":"4","key":"156_CR20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","volume":"172","author":"A Taieb","year":"2015","unstructured":"Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, et al. Superiority of ivermectin 1\u00a0% cream over metronidazole 0.75\u00a0% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103\u201310.","journal-title":"Br J Dermatol"},{"key":"156_CR21","first-page":"306","volume":"92","author":"ZD Draelos","year":"2013","unstructured":"Draelos ZD, Elewski B, Staedtler G, Havlickova B. Azelaic acid foam 15\u00a0% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis. 2013;92:306\u201317.","journal-title":"Cutis"},{"issue":"6","key":"156_CR22","first-page":"650","volume":"12","author":"J Fowler Jr","year":"2013","unstructured":"Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5\u00a0% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"156_CR23","first-page":"56","volume":"13","author":"A Moore","year":"2014","unstructured":"Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, Swinyer L, Liu H, Leoni M. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5 for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56\u201361.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"156_CR24","first-page":"33","volume":"14","author":"EA Tanghetti","year":"2015","unstructured":"Tanghetti EA, Jackson JM, Belasco KT, Friedrichs A, Hougier F, Johnson SM, Kerdel FA, Palceski D, Hong HC, Hinek A, Cadena MJ. J Optimizing the use of topical brimonidine in rosacea management: panel recommendations. Drugs Dermatol. 2015;14(1):33\u201340.","journal-title":"Drugs Dermatol."},{"key":"156_CR25","unstructured":"ClinicalTrials.gov. Safety and efficacy of AGN-199201 in patients with persistent erythema associated with rosacea. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02132117?term=allergan+rosacea&rank=1 . Accessed 21 June 2015."},{"key":"156_CR26","unstructured":"Galderma. Soolantra package insert, 2014. Available at: http:\/\/www.galdermausa.com\/pi\/soolantrapi.pdf . Accessed 8 Sept 2015."},{"key":"156_CR27","unstructured":"Bayer. Finacea foam, 15\u00a0% package insert, 2015. Available at: http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Finacea_Foam_PI.pdf . Accessed 8 Sept 2015."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-015-0156-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0156-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T19:07:20Z","timestamp":1748632040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-015-0156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s40257-015-0156-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]}}}